FDC Reports Launches Free Asian Pharma News And Regulatory Web Site
PharmAsia News to feature original reporting from FDC publications
Rockville, Md. - January 29, 2007 - FDC Reports, Inc. announces the launch of beta version of an Asian Pharma news and regulatory Web site, PharmAsia News. In response to growing demand for business and regulatory coverage of the rapidly expanding Asian biomedical industry, FDC Reports, the publisher of "The Pink Sheet," has launched PharmAsia News, a new beta Web site that provides free weekly articles, news summaries and updates about key developments in China, India, Japan and other Asian countries.
"When it comes to drugs, biotech, devices and other medical products, there is so much happening in this part of the world that anyone who is serious about understanding the future of the industry needs to pay attention now," said FDC's Editor-In-Chief, Joe Hecker.
PharmAsia News focuses primarily on pharma, it also features original reporting from various FDC publications including coverage of OTCs, biotech, devices, consumer health and regulatory issues. Additionally, PharmAsia News' free weekly email update includes news summaries, events, updates and more.
"This is such a great way for readers to sample a wide range of our content, keep up with Asia and take advantage of our new RSS feeds, that FDC has decided to roll this out immediately as a free beta site. We're really hoping that readers will make full use of this dynamic new product and share their thoughts and coverage needs with our editorial staff," added Hecker.
About F-D-C Reports
FDC Reports provides up-to-date information about the worldwide health care industry via its publications including The Pink Sheet®, The Gray Sheet®, The Rose Sheet®, The Tan Sheet®, and Pharmaceutical Approvals Monthly. The publications are read extensively by pharmaceutical and healthcare executives, policy-makers, and analysts seeking to understand the developments affecting the U.S. regulation and marketing of healthcare products and services. FDC Reports has one of the largest, most experienced, and most respected editorial teams reporting on the latest regulatory, legislative, and business news affecting the U.S. drug, biotechnology, medical device, nonprescription drug, nutritionals, and cosmetics industries.
FDC Reports, Inc. is part of Elsevier. Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, the company publishes more than 1,800 journals and 2,200 new books per year, in addition to offering a suite of innovative electronic products and online reference works.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com